FDA approves second drug for a site-agnostic indication;larotrectinib was tested across 17 cancer types November 30, 2018Vol.44 No.44By Paul Goldberg
Drugs & Targets FDA approves Empliciti + pomalidomide and dexamethasone for multiple myeloma November 09, 2018Vol.44 No.42
Drugs & Targets FDA grants Fast Track to selinexor for diffuse large B-cell lymphoma November 09, 2018Vol.44 No.42
Drugs & Targets Seattle Genetics submits sBLA for ADCETRIS in frontline treatment of CD30-expressing peripheral T-cell lymphomas November 09, 2018Vol.44 No.42
Drugs & Targets BMS, Infinity form collaboration to evaluate Opdivo + IPI-549 in urothelial cancer November 09, 2018Vol.44 No.42
Drugs & Targets ASCO, SITC release recommendations for reporting of immuno-oncology clinical trials November 09, 2018Vol.44 No.42
Drugs & Targets FDA’s digital tool seeks to help capture real world data useful in regulatory decision-making November 09, 2018Vol.44 No.42
Drugs & Targets Elsevier to integrate NCCN guidelines into Via Oncology November 09, 2018Vol.44 No.42
Clinical Roundup Stereotactic radiosurgery and surgical resection offer similar local control of brain metastases November 09, 2018Vol.44 No.42
